The Influenza Diagnostics Market is expected to maintain strong demand as seasonal influenza surveillance becomes a routine component of healthcare planning. The market is projected to increase from USD 1.94 billion in 2025 to USD 3.53 billion by 2035, registering a 6.15% CAGR during the forecast period.
The growing adoption of molecular diagnostics is transforming the competitive landscape. RT-PCR remains an important technology for hospital laboratories, while newer amplification methods are being developed to provide molecular-level accuracy in simpler and more decentralized testing environments.
Point-of-care testing is one of the most promising growth areas, with the segment forecast to expand at a 9.85% CAGR through 2035. Greater availability of rapid and molecular testing outside centralized laboratories could make influenza diagnosis more convenient for patients and healthcare providers.
North America is projected to retain its leadership, while Asia Pacific represents the fastest-growing regional opportunity at an estimated 8.40% CAGR. Rising laboratory investment in countries such as India and China is supporting broader access to modern diagnostic technologies.
The future market could increasingly focus on decentralized and at-home testing, multiplex respiratory panels, and AI-integrated diagnostics. These innovations may help expand testing access while enabling faster identification of influenza and other respiratory infections.
Gain valuable insights through comprehensive industry analysis:
Micro Guide Catheters Market Trends
Electrical Stimulation Devices Market Demand
